Application value of Abnormal Prothrombin Assay Kit (Chemiluminescence Immunoassay) in auxiliary diagnosis of liver cancer

Clinical Significance and Biomarker Background

Abnormal prothrombin, also known as des-γ-carboxy prothrombin (DCP) or PIVKA-II, is a molecule abnormally produced from prothrombin precursors due to reduced γ-glutamyl carboxylase activity under conditions of vitamin K deficiency or hepatocellular carcinogenesis. Numerous studies have confirmed that serum PIVKA-II levels are closely associated with the occurrence, progression, and prognosis of hepatocellular carcinoma (HCC). Compared with alpha-fetoprotein (AFP), PIVKA-II can still be positive in certain HCC patients who are AFP-negative or have low AFP levels, and combined detection of the two can improve the diagnostic sensitivity and specificity for early-stage HCC. Therefore, the abnormal prothrombin assay kit (chemiluminescence immunoassay) has become one of the commonly used detection tools in clinical laboratories.

Technical Advantages of Chemiluminescence Immunoassay

Abnormal prothrombin kits using chemiluminescence immunoassay (CLIA) are typically based on the double-antibody sandwich principle: PIVKA-II in the sample binds to the solid-phase antibody, then reacts with an enzyme-labeled or directly chemiluminescence-labeled detection antibody, generating a light signal through a luminescent substrate, with light intensity proportional to the analyte concentration. This method has the following characteristics:

High sensitivity: The photon quantum yield of the chemiluminescence system is far higher than that of traditional enzyme-linked immunochromatographic methods, enabling detection of PIVKA-II at levels as low as sub-ng/mL, which helps identify early microscopic lesions.

Wide linear range: Common kits have a detection range covering several ng/mL to several thousand ng/mL, meeting the testing needs of patients at different disease stages.

High degree of automation: When combined with a fully automated chemiluminescence analyzer, it enables random access sampling and batch processing, reducing manual operation errors and improving laboratory efficiency.

In addition, this method typically uses magnetic microparticles as the solid-phase carrier, which can shorten reaction time and reduce non-specific adsorption.

Clinical Application Scenarios and Rational Use

The abnormal prothrombin assay kit (chemiluminescence immunoassay) is mainly applied in the following scenarios:

Screening and early diagnosis of high-risk HCC populations: For example, in patients with chronic hepatitis B, hepatitis C, or cirrhosis, regular monitoring of PIVKA-II combined with AFP can improve the early detection rate.

Efficacy evaluation: After surgical resection or local ablation, serum PIVKA-II levels decrease significantly; if they do not decrease or rise again postoperatively, it suggests possible residual disease or recurrence.

Recurrence monitoring: Testing every 3 to 6 months after treatment completion, with continuous dynamic observation, provides reference for imaging examinations.

It should be noted that PIVKA-II is not an HCC-specific marker, and benign liver diseases (such as acute hepatitis, obstructive jaundice, and vitamin K deficiency) can also cause transient elevation. Therefore, clinical interpretation should be combined with imaging, medical history, and other laboratory indicators, avoiding isolated judgment. The manufacturer's instructions clearly state that this kit is intended for in vitro auxiliary diagnosis and should not be used as the sole basis for definitive diagnosis.

Rational Use and Compliance Considerations

According to medical device regulations in mainland China, the abnormal prothrombin assay kit (chemiluminescence immunoassay) belongs to Class II or Class III in vitro diagnostic reagents and must obtain registration certification from the National Medical Products Administration (NMPA) before it can be marketed and sold. Laboratories should perform performance verification before use, including precision, accuracy, linearity, and reference interval confirmation. In advertising, absolute terms such as "100% diagnosis rate" are strictly prohibited, and the clinical application scope and limitations of the test item should be objectively stated. Routine quality assurance measures include regular calibration, participation in external quality assessment, and strict adherence to reagent storage conditions (typically 2–8°C, protected from light).